JNJ vs KPTI
JNJ: A diversified global healthcare leader focused on innovative pharmaceuticals and advanced medical technologies to treat complex diseases. KPTI: Karyopharm Therapeutics develops novel cancer therapies using its proprietary XPO1 inhibition platform, with the lead drug XPOVIO currently used in multiple myeloma and a late-stage pipeline targeting myelofibrosis.
Side-by-side fundamentals
| Metric | JNJ | KPTI | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $259.36 | $0.3586 | |
| Market cap | $625.0B | $8M | |
| P/E as of 2026-10-20 | 30.09 | n/a | |
| Net margin FY2025, SEC XBRL | +28.5% | -134.2% | JNJ higher |
| Gross margin FY2025, SEC XBRL | +67.9% | n/a | |
| Operating margin FY2025, SEC XBRL | n/a | -62.1% | |
| ROE FY2025, SEC XBRL | +32.9% | n/a | |
| ROA FY2025, SEC XBRL | +13.5% | -180.8% | JNJ higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | 0.58 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +6.0% | +0.6% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | -2.4% | JNJ higher |
| Dividend yield as of 2026-09-02 | +2.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | JNJ higher |
| Beta as of 2026-09-02 | -0.03 | 0.80 | |
| 1-year return as of 2026-10-20 close | +33.9% | -94.5% | JNJ higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.